Cagrilintide
ProtocolProtocol design for Cagrilintide starts with pharmacokinetics and ends with calendar planning. The compound's ~7 days half-life via subq administration places it in the weekly-dosing bucket; cycle length is 8-12 weeks with a 4-week off-period; stack integration follows route compatibility and receptor non-overlap principles.
Key Takeaways
Scheduling lens: Cagrilintide's ~7 days half-life via subq places it in the weekly-dosing bucket. Mechanism: Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Selectively activates the amylin receptor (calcitonin receptor + RAMP1/3 complex). Slows gastric emptying, suppresses postprandial glucagon, and acts centrally in the area postrema to suppress appetite. The C16 fatty-acid sidechain enables albumin binding and once-weekly dosing. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Cagrilintide.
Daily and weekly timing
Cagrilintide with a ~7 days half-life pharmacokinetic profile sits in the weekly-dosing-friendly bucket. The schedule is best built around either 1x weekly SubQ, with consistency mattering more than the absolute clock time of any single dose.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Cagrilintide protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Cagrilintide schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
Stack scheduling with other compounds
When Cagrilintide is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.
The most-asked scheduling question for Cagrilintide in cycle design is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
For tapered cycles scheduling, Cagrilintide is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
Schedule design for Cagrilintide in daily timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
The most-asked scheduling question for Cagrilintide in cycle length is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | SubQ | 1.2-2.4 mg | 8–12 weeks on / 4 weeks off |
| Conservative starter | SubQ | 1.2-2.4 mg | 4–6 weeks initial cycle |
| Protocol focus | SubQ | 1.2-2.4 mg | 1x weekly SubQ |
| Maintenance phase | SubQ | 1.2-2.4 mg | Ongoing with periodic pauses |
Dose timing for Cagrilintide is less time-sensitive given the longer half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Cagrilintide stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- Cagrilintide + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Cagrilintide's mechanism in protocol / scheduling / cycling protocols.
- Cagrilintide + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Cagrilintide's mechanism in protocol / scheduling / cycling protocols.
- Cagrilintide + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Cagrilintide's mechanism in protocol / scheduling / cycling protocols.
- Cagrilintide + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Cagrilintide's mechanism in protocol / scheduling / cycling protocols.
Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy.
Lens-specific safety considerations for protocol / scheduling / cycling use of Cagrilintide: Gastrointestinal events most common (nausea, vomiting), generally lower than GLP-1 mono-therapy. Pancreatitis caution; avoid in pregnancy. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Cagrilintide | Long-acting amylin analogue | ~7 days | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
What if I miss a dose?
Daily timing for Cagrilintide?
When to integrate Cagrilintide into an existing stack?
Best practice for re-cycling?
How does Cagrilintide compare to BPC-157 and TB-500?
What should I look for in Cagrilintide sourcing and quality?
Start a Cagrilintide Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified Cagrilintide and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- ~4400 Da
- Sequence length
- 37 aa
- Half-life
- ~7 days
- WADA
- Not on prohibited list
- FDA
- Investigational (Phase III combined with semaglutide as CagriSema)
- Research
- Phase III trials underway
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Cagrilintide unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for Cagrilintide
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised